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a b s t r a c t
This paper explores the different identities adopted by connective tissue research at the University of
Manchester during the second half of the 20th century. By looking at the long-term redeﬁnition of a
research programme, it sheds new light on the interactions between different and conﬂicting levels in
the study of biomedicine, such as the local and the global, or the medical and the biological. It also
addresses the gap in the literature between the ﬁrst biomedical complexes after World War II and the
emergence of biotechnology. Connective tissue research in Manchester emerged as a ﬁeld focused on
new treatments for rheumatic diseases. During the 1950s and 60s, it absorbed a number of laboratory
techniques from biology, namely cell culture and electron microscopy. The transformations in scientiﬁc
policy during the late 70s and the migration of Manchester researchers to the US led them to adopt
recombinant DNA methods, which were borrowed from human genetics. This resulted in the emergence
of cell matrix biology, a new ﬁeld which had one of its reference centres in Manchester. The Manchester
story shows the potential of detailed and chronologically wide local studies of patterns of work to under-
stand the mechanisms by which new biomedical tools and institutions interact with long-standing prob-
lems and existing afﬁliations.
 2010 Elsevier Ltd. All rights reserved.
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1. Introduction
The investigation of contemporary biomedicine has been a main
concern in both historical and contemporary Science and Technol-
ogy Studies (STS). Historians and sociologists of biology, as well as
policy scholars, have investigated the interactions between biolo-
gists, physicians, research institutions, clinical sites and funding
agencies in the emergence of programmes expected to lead labora-
tory biology to the diagnosis and treatment of diseases. This has re-
sulted in a wide literature both in scope and approach: the
scholarship covers the secondhalf of the 20th century and addresses
the development of biomedicine from different perspectives.
One might distinguish between two levels of analysis: micro-
studies and wider characterisations of stages and structures in
the history of biomedicine. Within the latter approach, historians
have investigated the emergence of the ﬁrst ‘‘biomedical com-
plexes’’ after World War II and their connections with the changing
scientiﬁc and political priorities in Europe and the United States
(Beatty, 1991; Hannaway, 2008; Hardy & Tansey, 2006; Quirke &
Gaudillière, 2008). There is also a rich literature on the interactions
between laboratories and the pharmaceutical industry, their trans-
formations throughout the 20th century and the development of
drugs such as insulin, penicillin or anti-histamines (Bud, 2007;
Liebenau, 1987; Liebenau, 1989; Quirke, 2008; Swann, 1988). More
recently, historians and policy scholars have addressed the emer-
gence of biotechnology and how the advent of recombinant DNA
methods transformed the practice and economics of biomedicine
from the 1970s onwards (Collins, 2004; Gottweis, 1998a; Orsenigo,
1989; Wright, 1994). The scholarship on biotechnology is some-
times framed in terms of the emergence of a new form of
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knowledge production—more interdisciplinary and problem
oriented than the previous biomedical complexes—and of a ‘‘triple
helix’’ of interactions between the university, governments and
industry (Etzkowitz & Leydesdorff, 2000; Gibbons et al., 1994).
The micro-studies address the formation of more speciﬁc ‘‘plat-
forms’’ or ‘‘networks’’ oriented towards a disease or research prob-
lem (Keating & Cambrosio, 2006). These associations may result in
a particular medical innovation, in the emergence of a new disci-
pline or in institutional transformations. Thus, scholars have inves-
tigated the connections between laboratories and hospitals in the
investigation of cancer or sickle-cell anaemia (De Chadarevian,
1998; Löwy, 1996); and they have explored local conﬁgurations
of biomedical disciplines such as physiology immunology or
molecular biology (De Chadarevian, 2002; Kay, 1993; Tansey,
2008; Tauber & Podolsky, 2000). There are also a number of
anthropological studies on the emergence of recent molecular
diagnostic tools in laboratories and companies (Rabinow, 1996;
Rabinow, 1999; Rabinow & Dahn Cohen, 2005).
All these investigations share a concern with interactions be-
tween different and sometimes conﬂicting levels. A number of
studies address national and institutional biomedical traditions,
the mobility of researchers and the policy role of institutions such
as the Medical Research Council (UK), the Centre National de la
Recherche Scientiﬁque (France) or the National Institutes of Health
(USA) (Austoker, 1989; Gaudillière, 2002; Picard, 1990; Soon Park,
2008; Timmermann, 2008). However, there is an ongoing debate
on the potentials and limitations of these studies to capture more
global transnational trends in the development of biomedicine (e.g.
De Chadarevian & Strasser, 2002). The way in which emerging
technologies such as cell culture, the electron microscope or, more
recently, recombinant DNA have transformed and been trans-
formed by biomedical practice at different stages of the 20th cen-
tury is another main concern of the literature on biomedicine
(Clarke & Fujimura, 1992; Jordan & Lynch, 1992, 1993; Landecker,
2007; Rasmussen, 1997). Scholars have also combined historical
and sociological methods to explore the complex interactions be-
tween the medical and the biological in the development of treat-
ments, diagnostic instruments and clinical trials (Keating &
Cambrosio, 2007; Löwy, 1993, 1996; Pickstone, 1992).
This paper considers two interwoven stories in one locality to
show the interactions between a long-term research programme
and the reorganisation of biomedical sciences in a major British
university. I draw on several of the research problems and investi-
gations just discussed, and connect them in ways which may point
to more integrated histories. For this purpose, I address a particu-
larly unexplored ﬁeld: the development of the research on bone,
tendon, cartilage and other connective tissues aimed to attach dif-
ferent and distant parts of the body.
I focus on a team at the University of Manchester which started
working on connective tissue after World War II. Its research was
initially centred on rheumatism and arthritis, but gradually
evolved to a more general programme named cell-matrix biology
in the 1980s. This renaming coincided with a profound institu-
tional reform which boosted biology in Manchester and led to
the emergence of a new School of Biological Sciences at the Univer-
sity. The connective tissue group expanded in this new institu-
tional setting and in 1996 formed a Wellcome Trust Centre for
Cell Matrix Research. In this new Centre, the Manchester research-
ers utilised long-standing tools for the study of connective tissue
together with newer recombinant DNA techniques.
By following the trajectories of the connective tissue research-
ers and their technologies, I will document the transformation of
a ﬁeld which emerged with a clear clinical motivation and evolved
towards a more fundamental biomedical agenda. Crucially, I will
analyse the interactions between institutional transformations,
the introduction of new techniques, and the changing practices
and concerns of the Manchester scientists. The study will be fo-
cused on a local setting—the University of Manchester—but will
explore the exchanges and interactions between its researchers
and other institutions in Britain and the United States. The broad
chronological scope selected for this investigation (late 1940s to
mid 90s) will allow me to integrate the scholarship on post-World
War II with that on biotechnology and show how the genealogies
of the connective tissue researchers were affected and reciprocally
affected wider transformations in biomedicine.
My point of departure will be oral histories and the published
papers of the connective tissue researchers. These sources will be
combined with funding applications, laboratory protocols and
other archival materials which will show how the Manchester
researchers conducted their work and presented it to biomedical
funding agencies. I will also build on the rich historical research
on science and technology in Manchester (for guides see Pickstone,
1989, 2007b; Pickstone & Butler, 2005), as well as previous studies
on modes of work and the transformation of research programmes.
This historiography operates at various scales: from big picture
history of science, technology and medicine (Pickstone, 2000,
2007a), through comparative studies of recent academic biology
in Britain (Wilson & Lancelot, 2008), to a detailed analysis of the
organisational politics of the University of Manchester (Wilson,
2008).1
The paper will be organised in three parts:
– Part I will explore the status of connective tissue research as
introduced to Manchester in the late 1940s and its development
up to the late 70s—for which period, Manchester biomedical
research was relatively weak compared to physical sciences
and clinical medicine (Pickstone, 2007b; Wilson & Lancelot,
2008).
– A major academic restructuring during the mid 1980s strength-
ened the biomedical departments in Manchester; it was
intended to clear the way for the introduction of the new tech-
niques of molecular biology (Wilson, 2008; Wilson & Lancelot,
2008). Part II of my paper will follow these transformations
and the migrations of the connective tissue scientists to the
United Sates in order to learn new recombinant DNA methods.
– Part III will focus on the return of the Manchester scientists and
the combination of recombinant DNA with other techniques for
the analysis of connective tissue. This resulted in the redeﬁni-
tion of connective tissue as cell-matrix biology and the creation
of a centre funded by the Wellcome Trust.
2. Rheumatism and the origins of connective tissue research
The ﬁrst incarnation of connective tissue research in Manches-
ter was the Centre for Chronic Rheumatic Diseases, created in 1947
with a grant from the Nufﬁeld Foundation. Rheumatism and arthri-
tis had been main concerns in Britain and other Western countries
sinceWorldWar I. They were widespread in the trenches and often
associated with tuberculosis, pneumonia and heart diseases. Dur-
ing the 1920s and 30s, rheumatism and arthritis were recognised
as common diseases of industrial workers and as major causes of
unemployment, prompting the foundation of disease speciﬁc char-
ities, notably the Empire Rheumatism Council (ERC) (Cantor, 1991;
Dixon, 2000, pp. 13–15; Schubert & Hamerman, 1968, pp. vii–x).
1 Other local studies which have inspired my work are those on the development of biomedicine in Spain and Italy during the second half of the 20th century (e.g. Capocci &
Corbellini, 2002; Santesmases & Muñoz, 1997).
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This history, and the renewed importance of rheumatism and
arthritis among troops during World War II, led the British Govern-
ment to place both diseases among the priorities of the National
Health Service, which was created after the war to rationalise
and support healthcare. Basic biomedical research was also fos-
tered, as it was in Continental Europe and the US. The main re-
search funders of arthritis and rheumatism in Britain were the
Medical Research Council and the health-related charities. Lord
Nufﬁeld, a leading businessman from the motor industry, used
his Foundation to support specialised research institutions in var-
ious British universities and hospitals (Cantor, 1991, pp. 228–
231; Dixon, 2000, pp. 128–129). The Manchester Centre was one
of them and among its ﬁrst initiatives was a clinical trial with cor-
tisone, a hormone which was established as a potential therapeutic
agent in 1948 (Cantor, 1992, pp. 165–167).2
The Rheumatism Centre was located in the University’s Faculty
of Medicine and associated with the Royal Inﬁrmary, the city’s
main teaching hospital. Its Chairman, Jonas Kellgren, became the
ﬁrst Professor of Rheumatology in Britain, thanks to an endowment
from the ERC. Kellgren was a clinician who had served in World
War II and was interested in the epidemiology of rheumatic pa-
tients: part of his Manchester research was on coal miners from
the surrounding region of Lancashire. In his study of the organisa-
tion of biology in Manchester, Duncan Wilson has shown that the
Centre was conceived as combining clinical practice and funda-
mental biological research. Kellgren did so by recruiting investiga-
tors from several departments of the University (Wilson, 2008, pp.
84–85).
The main research object at the Centre was collagen, a ﬁbrous
protein which was by then considered the most important
component of connective tissue.3 Collagen had been the focus of
microscopic observations since the 19th century and with the devel-
opment of biochemistry, researchers attempted to determine its
composition, as they were doing for other proteins during the ﬁrst
decades of the 20th century. Collagen was difﬁcult to investigate be-
cause it was not soluble, but prominent protein chemists such as
Albert Neuberger and Ralph Consden were able to apply the newly
invented techniques of amino acid analysis and column chromatog-
raphy (Piez, 1997, pp. 85–90; Grant, 2007, pp. 204–205).
Another approach to collagen in the early 20th century was
X-ray crystallography, pioneered by William Henry Bragg and his
son Lawrence. In the 1920s and 30s, William worked in London,
whilst Lawrence had succeeded Ernest Rutherford as Professor of
Physics at Manchester. Most of the Manchester work on X-ray
crystallography was on inorganic compounds, and some was
industry-related, but there seems to have been little connection
with local industrial research, perhaps because its focus was cotton
(and thus cellulose). It was across the Pennine Hills at Leeds, for
wool textiles rather than cotton, that William Astbury harnessed
X-ray crystallography for the study of industrially relevant ﬁbres,
among them collagen.4
Astbury, a former student of W.H. Bragg, attempted to ﬁnd a
correspondence between the sequence of amino acids and spatial
conformation of collagen (Astbury, 1940, 1957, 1961; Bernal,
1963, pp. 14–15; Wilson, 2008, pp. 83–84). Between the 1930s
and 50s, a number of X-ray crystallographers proposed tentative
structuralmodels for collagen, among them Linus Pauling at Caltech
and J.T. Randall at the biophysics unit of King’s College London—the
same department where Maurice Wilkins and Rosalind Franklin
were investigating the structure of DNA (Pauling & Corey, 1951;
Randall & Fitton, 1953). In 1955, Indian biophysicist G.R. Ramachan-
dran published a triple helical model for collagen shortly before a
similar one was proposed by Francis Crick and Alexander Rich
(Ramachandran & Kartha, 1955; Rich & Crick, 1955; Sarma, 1998,
pp. 43–62). This model resembled the double helical structure that
Crick had postulated for DNA with James Watson two years before
(Watson & Crick, 1953a, 1953b).5 Such was the proliferation of
models at that time that it was agreed that crystallographers were
only entitled to one proposal per molecule (Rich, 1998).
Work at the Rheumatism Centre in Manchester was inspired by
these early investigations on collagen. The lines of research in-
volved characterisation of collagen in bone and cartilage of rheu-
matic patients, applying tissue culture techniques and drawing
on the strong tradition on histopathology at the University’s Fac-
ulty of Medicine (Baker, 1956; Wilson, 2008, pp. 8–11). Research-
ers also used the electron microscope, which derived from war-
related work on physics and was then spreading in biomedicine.
This apparatus helped bridge cytology and histology (Rasmussen,
1995, pp. 385–390, 1997, ch. 3), and to place the investigations
on collagen within the emerging ﬁeld of cell biology. The Manches-
ter researchers originally used the electron microscope in cooper-
ation with Astbury, but gradually developed their own expertise
and an independent University department of Medical Biophys-
ics—engaged with the characterisation of collagen and other bio-
logical molecules (Kellgren, Ball, Astbury, Reed, & Beighton,
1951; Pullan et al., 1983). Kellgren also established a line of re-
search on collagen biochemistry at the Rheumatism Centre.
2.1. The collagen group and the biosynthesis systems
The biochemical research at Kellgren’s Centre was conducted by
David Jackson, who after war service in the Air Force took a degree
in Manchester jointly taught by the Departments of Chemistry and
Physiology (Wilson, 2008, pp. 84–85). That both of these depart-
ments taught biochemical students reﬂects the historic strengths
of Manchester in both chemistry and medicine, and contrasts with
the situation in Cambridge, where biochemistry and other preclin-
ical disciplines ﬂourished and differentiated more easily. Jackson
was hired by Kellgren shortly after the foundation of the Centre
and in 1957 left Manchester for a long postdoctoral stay in the
US. He worked with the surgeon Englebert Dunphy at the Boston
City Hospital and at the University of Oregon on wound healing—
another property of collagen.6
When Jackson returned to Manchester in 1965 he organised his
own research group focused on the biochemistry of connective tis-
sue. It was located in the Department of Medical Biochemistry,
which had recently been split off from Physiology. The group’s
work initially involved composition studies of collagen and its sur-
rounding molecules, using enzymes, chromatography and amino
acid analysis (Grant & Jackson, 1968) (see Fig. 1).
2 D. Jackson (undated) Unpublished memoirs (Michael Grant’s personal archive, Faculty of Life Sciences, University of Manchester, UK).
3 Collagen was not the only focus of connective tissue research in Manchester during the late 1940s and 50s. The University also hosted research on mucopolysaccharides,
proteins surrounded by sugars which also integrate connective tissue. This latter work was conducted in both the Rheumatism Centre and other departments of the University
whose connections with Kellgren’s group were sometimes weak (Scott, 2007; D. Ashhurst, interview with author, Wellcome Trust Library, London, UK, 2008).
4 Collagen was the component of commercial products which were industrially relevant during the late 19th and early 20th centuries. Apart from wool, other industries which
conducted biochemical and biophysical research on collagen—sometimes in cooperation with academia—were devoted to glue, leather, meat and photographic gelatine (Ashhurst
& Bailey, 2005).
5 The absence of an extended time gap between the proposals by Ramachandran and Crick–Rich gave rise to a controversy over the priority of the triple helical model of
collagen. A number of commentators have argued that it is normally attributed to Crick and Rich due to their ﬁrst-world institutional afﬁliation and popularity, given their
involvement in molecular biology and the postulation of the double helix of DNA (Balaram, 2004; Sarma, 1998, pp. 63–70).
6 D. Jackson (undated) Unpublished memoirs (Michael Grant’s personal archive, Faculty of Life Sciences, University of Manchester, UK).
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One of Jackson’s ﬁrst recruits was Michael Grant, a plant bio-
chemist educated at the University of Manchester Institute of Sci-
ence and Technology—UMIST, semi-independent from the
University—7and then in Oxford (Wilson, 2008, p. 85). Grant had
been invited to an interview for a position in plant biochemistry at
another department of the University, but ended up accepting a post
in Jackson’s group. Jackson was particularly interested in Grant’s
expertise in cell culture and his techniques for the analysis of large
sticky molecules of the plant cell wall. At that time, Jackson was
planning to expand his research from structural to more metabolic
biochemistry, including the problem of ‘‘collagen synthesis’’ (Grant,
2007, p. 204).8
Grant recalls that when he arrived in 1966 as an Assistant Lec-
turer, the group was small and mainly focused on teaching. Shortly
after his arrival, he applied for a stay in a laboratory in the Univer-
sity of Pennsylvania, associated with the Philadelphia General Hos-
pital. It was led by Darwin Prockop, then emerging as a key ﬁgure
in collagen research and working on the problem of synthesis
through an innovative cell culture technique (Grant & Prockop,
1972). It was with Prockop, in the grant-oriented culture of the
United States, that Grant learned ‘‘how to do research’’. On his re-
turn to Manchester in 1972, he too studied the synthesis and secre-
tion of collagen.9
The development of cell culture techniques during the 20th
century—and of antibiotics after WWII—allowed biologists to
maintain cells relatively easily, so they could be used as research
objects, and circulated between laboratories (Landecker, 2007,
chs. 3–4). Grant’s new investigations in Manchester involved
extracting cells from tendons of early chick embryos and forming
collagen ‘‘synthesising systems’’, ﬁrst in vivo and then in vitro. He
also labelled collagen amino acids with radioactive isotopes in or-
der to detect them (Grant, 2007, p. 208; Grant, Kefalides, & Proc-
kop, 1972, 1973). Synthesising systems had been originally
conceived and used in hospital-related investigations on cancer
and during the 1950s and 60s, they gradually spread to become a
common tool among biochemists (Rheinberger, 1993, 1997, chs.
3–4). Radioactive isotopes had been widely introduced in biomed-
icine after WWII (Creager & Santesmases, 2006).
During the second half of the 1970s, Grant started to explore
‘‘the control of collagen biosynthesis’’ and the roles of genes in
the formation of the protein. His research then shifted to the ‘‘iso-
lation and characterisation’’ of collagen’s messenger RNA in order
to analyse its translation to protein (Grant, 2007, pp. 207–208;
Cheah & Grant, 1982; Harwood, Grant, & Jackson, 1975). Grant’s
new research did not initially involve altering the structure of
the molecules, though new recombinant DNA and RNA techniques
were then emerging in molecular biology. It was in part, however,
to facilitate the local development of molecular biology that Grant
became one of the agents in a profound transformation of biomed-
ical research at the University of Manchester.
3. The reorganisation of Manchester biomedicine
The reform of the University of Manchester has been studied in
detail by Duncan Wilson and Gaël Lancelot. Up to the late 1970s,
the major scientiﬁc strengths of the University were in chemistry
and physics, with departments located at the Faculty of Science
and strongly connected to the local industry. Clinical work and
teaching at the Faculty of Medicine were also praised. However,
the biological and preclinical sciences were relatively weak, com-
pared to Cambridge, Oxford and University College London, as well
as some new British universities where ambitious biology depart-
ments had been created.10
Manchester’s Zoology and Botany Departments were marginal
in the Science Faculty, and found cooperation difﬁcult. In the Med-
ical Faculty, research in anatomy, physiology, pathology and bacte-
riology was often overshadowed by the clinical interests and was
less of a priority than service work for medicine. These departmen-
Fig. 1. David Jackson (left) and Jonas Kellgren (right), researchers at the Centre for Chronic Rheumatic Diseases (University of Manchester Archives. Reproduced by courtesy
of the University Librarian and Director, The John Rylands University Library, University of Manchester, UK).
7 UMIST derived from the Manchester College of Science and Technology, which was owned by the City Council and linked with the University of Manchester from 1905. After
World War II, the College became independent of the city government, and in 1955 adopted the name UMIST. In 2004, UMIST and the University of Manchester were merged
(Wilson, 2008, pp. 15–16 and ch. 9).
8 Jackson had been interested in the synthesis of collagen since, at least, the late 1950s, but at that time referred to it as ‘‘the formation’’ or ‘‘the biogenesis’’ of collagen, quoting
19th century microscopists such as Theodor Schwann and Rudolf Virchow (Jackson, 1957 and id.: ‘‘The biogenesis of collagen’’. Proof for the Conference of the British Gelatine and
Glue Research, University of Cambridge, 1957. Francis Crick’s Papers, Wellcome Trust Archives, London, UK ﬁle number PP/CRI/E/1/5/3).
9 M. Grant, interview with author, Faculty of Life Sciences, University of Manchester, UK, 2008.
10 For a broader perspective of the University of Manchester—born as Owens College in 1851—see Pullan, Ford, & Leahy (2007), Pullan & Abendstern (2000, 2004), and Pickstone
(2007b).
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tal structures were common in provincial European and British
universities, many of which undertook parallel reforms (Lancelot,
2007; Wilson & Lancelot, 2008, pp. 105–107).
The split between the Medical and the Science Faculty hindered
the formation of biomedical programmes in Manchester. This was
especially true in biochemistry, for which two departments had
emerged at the University: Medical Biochemistry from Physiology,
and Biological Chemistry from a large Chemistry department with
signiﬁcant historic strengths in organic analysis and synthesis, as
well as in fermentation studies—Chain Weizmann developed there
the fermentation process to produce acetone, a substance of para-
mount importance for military operations during World War I.11
Staff in Medical Biochemistry and Biological Chemistry had limited
interactions: they lived in different buildings, were administered
by different Faculties, and used different research facilities (Wilson,
2008, pp. 14–15).
The Departments of Botany and Zoology had attempted to col-
laborate over genetics and cell biology, but personal animosities
interfered. For the most part, staff in the two departments pursued
structural analyses and comparative physiological research on
plants and on animals, rather than the studies in cytology, cell
physiology, genetics or immunology which were elsewhere bring-
ing biology departments closer to preclinical studies. Though some
zoologists and botanists shared an electron microscope with Jack-
son’s group, there was little collaboration (ibid., p.15).
Manchester biomedicine was radically reconﬁgured in the
1980s for three main reasons. Firstly, Botany, Physiology, Medical
Biochemistry and a new department of basic Dental Sciences came
to be led by young professors—among them Grant—who agreed on
a reform agenda. Secondly, a microbiologist, Mark Richmond, was
appointed Vice-Chancellor of the University; as a former Govern-
ment Advisor on genetic manipulation, he considered that the bio-
medical sciences could only prosper by using the new recombinant
DNA techniques that had emerged in molecular biology. Thirdly,
thanks to increasing budget cuts imposed by the new Government
of Margaret Thatcher, the research outputs of university depart-
ments came under increasing scrutiny. National mechanisms were
created to compare outputs and then to fund accordingly. That
Manchester’s biological and medical sciences ranged from average
to poor undercut the arguments of those who did not favour reor-
ganisation (ibid., ch. 3; Wilson & Lancelot, 2008, pp. 97–101).
Following Jackson’s retirement in 1981, Grant became head of
Medical Biochemistry and of the connective tissue group. By that
time, the Department of Biological Chemistry had been renamed
Biochemistry. In 1982, along with Christopher Pogson, the head
of Biochemistry, Grant arranged to create a uniﬁed department
that was jointly administered by the Faculties of Science and Med-
icine, and named Biochemistry. Four years later, in 1986, the young
professors and Richmond agreed a major reorganisation of bio-
medical sciences. A School of Biological Sciences was created with
four departments: (1) Biochemistry and Molecular Biology; (2) Cell
and Structural Biology; (3) Physiological Sciences, and (4) Environ-
mental Biology.
The previous departments, in both the Faculties of Science and
Medicine, were dissolved and their staff asked to redistribute
themselves among the departments of the new School. Almost all
the researchers in the uniﬁed Department of Biochemistry joined
Biochemistry and Molecular Biology, whereas the staff from the
Faculty of Medicine mainly went to Physiological Sciences. Most
of the botanists and zoologists went respectively to Cell and Struc-
tural Biology and to Environmental Biology (Wilson, 2008, pp. 24
and ff.; Wilson & Lancelot, 2008, pp. 98 and ff.).
The reform was well received within the University except for
the Department of Anatomy, whose staff did not wish to subordi-
nate their identity to molecular biology. John Scott, a researcher
who had joined Jackson’s group in the mid 1970s, with a new Chair
of Chemical Morphology, moved to the Chemistry Building in 1986,
outside the new School of Biological Sciences. He maintained a bio-
chemical and biophysical approach to connective tissue using elec-
tron microscopy, but not incorporating recombinant DNA
techniques (Scott, 2007). Staff in the new department of Environ-
mental Biology—which hosted most of the zoologists—felt unap-
preciated, partly for not introducing recombinant DNA methods;
most of its researchers left the University after a second reform
in 1993, which dissolved the departments of the new School and
created a Faculty of Life Sciences without departments, just re-
search groups (Wilson & Lancelot, 2008, pp. 101–105).
It is worth noting that neither Richmond, nor any of the young
professors were themselves molecular biologists. They were a new
generation of researchers aiming to apply the new recombinant
DNA techniques to problems they were already investigating from
other perspectives. They did not seek to create a molecular biology
centre or department, like the Laboratory of Molecular Biology of
Cambridge (LMB) or the Department of Molecular Biology of the
University of Edinburgh, foundedduring the1960s (DeChadarevian,
2002). Instead, Manchester and other British and European
universities—such as Shefﬁeld or Paris—created uniﬁed biomedical
schools or departments where recombinant DNA and other tech-
niques of molecular biology were introduced as shared resources
and oriented towards the research interests of each group (Lancelot,
2007; Wilson & Lancelot, 2008, pp. 105–107).12
By looking at Manchester, or the other universities which
adopted similar reorganisations, one can see that the reform
helped redeﬁne programmes which were initially outside the
scope of molecular biology and the new recombinant DNA tech-
niques. One of these programmes was connective tissue research,
which started adopting recombinant techniques in the late
1980s. By studying the genealogy of these techniques and their
introduction into Manchester, one can see how the dialogue be-
tween recombinant DNA and pre-existing problems in the ﬁeld
of connective tissue shaped patterns of work within and beyond
the new organisation of the University.
3.1. The transformation of collagen research
The University reform coincided with major changes in the
work of the connective tissue group. From the later 1970s, Grant
and his co-workers increased their focus on messenger RNA
(mRNA) in their in vitro synthesis systems. They aimed to isolate
the mRNA involved in the formation of different types of collagen
(Cheah & Grant, 1982; Harwood et al., 1975).13 Within this line of
research, Grant hired as a postdoctoral fellow Raymond Boot-
Handford, who had completed a PhD on the metabolism of diabetes
at University College London. They started working on the role of the
collagen which coats the blood vessel walls in heart complications
following diabetes. Thus the move towards nucleic acids coincided
11 Research on fermentation was also a main strength of UMIST, where Grant had studied biochemistry as an undergraduate. UMIST possessed a strong tradition in biochemistry
and this descended from the department of brewing science that its antecedent, the Manchester College of Science and Technology, had opened during the interwar years
(Wilson, 2008, pp. 15–16; see note 7).
12 US universities such as Berkeley or Stanford also reorganised their departmental structures in the face of the developments in molecular biology. These reorganisations,
however, occurred in the 1960s and 70s, preceding those in Europe (Trow, 1984; Vettel, 2004).
13 There are more than 25 known types of collagen involved in the formation of different tissues—e.g. bone, skin, cartilage or tendon. The diversity of this molecule began to be
known in the mid 20th century and, from the 1970s onwards, researchers specialised in speciﬁc types of collagen (Grant, 2007, pp. 204–207).
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with a broadening of the clinical interests of the group, from rheu-
matism to diabetes and other diseases which were becoming prior-
ities in the 70s and 80s, within the struggle against obesity and other
emerging health problems in Western societies.
Their interest in nucleic acids remained, however, subordinated
to protein chemistry. During the ﬁrst half of the 1980s, mRNA was
used to access the different collagens and their alterations in dia-
betes and other diseases. One of the ﬁrst experiments of Grant
and Boot-Handford was to measure rates of collagen synthesis in
systems obtained from diabetic and healthy rats. Grant also began
to use monoclonal antibodies to react with the collagen alterations
caused by diabetes (Grant, 2007, p. 209).
Both investigators became increasingly persuaded that to de-
velop their programme it was necessary to shift the focus of re-
search ‘‘from the perspective of proteins to that of genes’’. The
ﬁrst proposals of a University reform and the emphasis of such pro-
posals on recombinant DNA led them to believe that if the genes
responsible for diabetes could be isolated, then ﬁnding their muta-
tions would be simpler than looking for the resulting proteins. DNA
and RNA could by then be tackled in the laboratory thanks to the
emergence, among others, of complementary (cDNA) cloning and
sequencing techniques which allowed researchers to obtain DNA
fragments and to analyse their nucleotide structure. These tech-
niques, however, were only vaguely known by the Manchester
researchers.14
Grant decided that Boot-Handford should apply for a stay in the
laboratory of Darwin Prockop, the researcher from whom he had
himself learned the collagen synthesis techniques. Prockop’s group
had signiﬁcantly changed since Grant’s stay in the early 1970s. In
1973, it had moved to the Rutgers Medical School in New Jersey,
where Prockop had been appointed Director of the Centre for Hu-
man Molecular Genetics. The group in Rutgers used recombinant
techniques extensively for obtaining and characterising the DNA
fragments which constituted the genes producing defective colla-
gens in various diseases. Boot-Handford describes the laboratory
after his arrival, in 1985, as a large-scale organisation with ‘‘visitors
from all around the world’’ learning the techniques.15
The introduction of recombinant DNA into Prockop’s group pre-
sented complex genealogies. Up to the late 1970s, the team had
continued to work on collagen synthesis and some of its members
were unenthusiastic about the emergent recombinant techniques.
Bjorn Olsen, one of Prockop’s ﬁrst collaborators, recalls that shortly
after moving to Rutgers he was asked to teach Nucleic Acid Bio-
chemistry to medical undergraduates, a course which other mem-
bers of the group regarded as ‘‘boring’’ and unrelated to collagen
research. This indifference, according to Olsen, was due to the fact
that by the mid-late 70s the dominant perception among connec-
tive tissue researchers was that the recombinant DNA techniques
only worked in microorganisms. At that time, ‘‘it was not clear’’
to themwhether these techniques would be suitable to chicks, rats,
or the other complex multicellular organisms with which connec-
tive tissue scientists normally worked.16
This perception reﬂects the problematics in the circulation of
techniques between two largely non-interacting communities:
molecular biologists and connective tissue researchers. Despite
Francis Crick having proposed a triple-helical model for the struc-
ture of collagen in the mid 1950s (see above), he subsequently
identiﬁed his research trajectory and the disciplinary formation
of molecular biology with DNA, its double helix and the further
achievements around this molecule. In his autobiography, he states
that despite the apparent similarities between both helical struc-
tures, ‘‘in a very real sense collagen is not as important a molecule
as DNA’’ (Crick, 1988, p. 67). Crick and other self-declared founders
of molecular biology—including Rich—have retrospectively consid-
ered collagen only an incidental interest in their careers.
Connective tissue researchers, reciprocally, remained only dis-
tantly aware of the developments in molecular biology and this led
them to associate recombinant DNA with the microorganisms—
bacteria or bacteriophage viruses—with which molecular biologists
had worked during the golden era of this discipline in the 1960s.
However, by the time Olsen was preparing his undergraduate
syllabus,17molecular biologistswere gradually shifting their research
interests to multicellular organisms. This move, known as the ‘‘the
mass migration’’, shaped the ﬁrst attempts to producing recombinant
molecules, which combined microbial DNA with fragments obtained
from frogs and other complex eukaryotic organisms (Morange,
1997; Yi, 2008, pp. 383 and ff.).
During the mid 1970s, molecular biologists were also increas-
ingly urged by political authorities to ﬁnd medical applications
to their techniques. The US President Richard Nixon had declared
the war on cancer and, by the end of the decade, the ﬁrst biotech-
nology companies were founded, with the explicit aim of ﬁnding
diagnostic and pharmacological applications of recombinant
DNA. This triggered a large restructuring of biomedical complexes
in the US and Europe, and led researchers from different disciplines
to adopt the recombinant techniques (Gottweis, 1998b, pp. 107
and ff.; Kenney, 1986; Wright, 1998, pp. 94–95; Yi, 2008, pp.
592–593).
Human geneticists were among the ﬁrst in introducing recom-
binant tools. The new medical and eukaryotic approach of molec-
ular biology led them to initiate a ‘‘hunt’’ of the genes causing
different hereditary diseases. Such gene location had been a per-
manent goal in the history of genetics and researchers had devel-
oped different non-molecular means throughout the 20th
century: statistics, family pedigrees and chromosomal images,
among others (Kevles, 1995 [1985], pp. 264 and ff., 1992; Cook-
Deegan, 1994, ch. 2; Harper, 2008). Human genetics also seems
to have provided the bridge through which recombinant DNA per-
meated connective tissue research.
At the same time Olsen was learning and teaching molecular
biology (1975 and 1976), Prockop left Rutgers for a temporary stay
at the National Heart and Lung Institute of the National Institutes
of Health (NIH), a federal structure of government laboratories
with substantial expertise in microbiology and human genetics.
The seminar series at each of the specialist Institutes were open
to all researchers and Prockop, who had initially visited to study
the role of collagen in heart and lung diseases, recalls having
learned key techniques from another group working on atypical
haemoglobins.18 This group sought to isolate and analyse the gene
causing sickle cell anaemia. For this purpose, its researchers applied
to mRNA of patients complementary (cDNA) cloning and determined
the nucleotide sequence of the resulting DNA fragments.
Prockop was enthusiastic about applying recombinant tech-
niques to collagen when he returned to Rutgers. In 1980 and
1981, he wrote a number of articles advocating cloning and
sequencing as the future for connective tissue disease research
14 M. Grant and R. Boot-Handford, interviews with author, Faculty of Life Science and Wellcome Trust Centre for Cell Matrix Research, University of Manchester, UK, 2008.
15 R. Boot-Handford, interview with author, Wellcome Trust Centre for Cell Matrix Research, University of Manchester, UK, 2008.
16 B. Olsen, interview with author, Harvard Medical School, US, 2008.
17 Olsen subsequently renamed his course Nucleic Acid Biochemistry and Molecular Biology. He was elected twice lecturer of the year by his students (B. Olsen, interview with
author, Harvard Medical School, US, 2008).
18 D. Prockop, interview with author, Philadelphia, US, 2008.
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(Prockop, 1980). The techniques for the study of proteins, such as
amino acid analysis, could become ‘‘obsolete’’ in the face of the
new approach (Prockop, 1981). This feeling was common in other
areas of biomedical research—such as immunology or develop-
mental biology—which began focusing on genes isolated through
recombinant DNA rather than on their protein products (García-
Sancho, 2008, pp. 162–166; Gilbert, 1996; Löwy, 1996; Morange,
1997, pp. 389 and ff.; Tauber & Podolsky, 2000).
In 1980, Prockop organised an international meeting on ‘‘gene
families of collagen’’ which brought to Rutgers haemoglobin scien-
tists, experts in recombinant DNA and collagen researchers, some
of whom had already started to clone and sequence genes for this
protein (Boedtker, Crkvenjakov, Last, & Doty, 1974; Lehrach et al.,
1978; Prockop & Champe, 1980). Prockop himself hired Francesco
Ramirez, an expert in cDNA cloning who had been working at
Columbia University on the application of this technique to hae-
moglobin. The Prockop group then focused on cloning and
sequencing the genes responsible for collagen diseases such as
the bone condition Osteogenesis imperfecta. Olsen, who at that time
headed a neighbouring laboratory at Rutgers, also abandoned his
previous work on electron microscopy and took up the cloning
and sequencing of collagen genes.19
Prockop did not interact directly with molecular biologists until,
in 1986, he moved back to Philadelphia to chair the Department of
Biochemistry and Molecular Biology at Jefferson University. Boot-
Handford had arrived a year before; in both New Jersey and Phila-
delphia he learned how to measure levels of mRNA expression—his
initial goal—and how to make and screen cDNA libraries. Upon his
return to Manchester in the late 80s, he abandoned rats and diabe-
tes, and associated again with Grant to obtain cDNA clones of the
gene for a speciﬁc type of collagen—collagen X—which was in-
volved in bone formation. They were now competing with Olsen’s
group at Rutgers. In 1991, the Manchester teamwas the ﬁrst to iso-
late the bovine gene and then the human (Thomas, Kwan, Grant, &
Boot-Handford, 1991; Thomas, Cresswell, et al., 1991b).
When asked why he did not move to a British molecular biol-
ogy institution to learn the recombinant techniques, Boot-Hand-
ford argues that Prockop’s group was already known by Grant
and ‘‘spoke the same language’’.20 This highlights the complexity
of the trajectories in the introduction of recombinant DNA, the role
of professional networks and the importance of ‘‘centres of calcula-
tion’’ (Latour, 1987, ch. 6). Furthermore, in their circulation, the
new techniques interacted with pre-existing lines of research and
were applied to problems of connective tissue, such as collagen
synthesis.
The adoption of cloning and sequencing by connective tissue
researchers was, thus, negotiated in complex ways during the
mid and late 1970s. The new techniques were repackaged in a
discipline—human genetics—whose medical orientation and model
organisms—rats and humans—were closer to the interests of con-
nective tissue researchers. Molecular biologists, additionally, had
adopted multicellular organisms and medical concerns, and this
widened their research scope, displacing their ‘‘descriptive level
from the molecule to the cell’’ (Morange, 1997, p. 369). This dis-
placement and subsequent redeﬁnition of the cell was crucial in
the new identity that connective tissue research adopted in the
1980s.
4. From connective tissue to matrix biology: the redeﬁnition of
a research ﬁeld
Boot-Handford returned to Manchester in 1987, shortly after
the reorganisation of the biomedical sciences in the University. Fol-
lowing the creation of the new School of Biological Sciences (1986),
the connective tissue team was assigned to the Department of Bio-
chemistry and Molecular Biology and renamed Extracellular Ma-
trix and Tumour Biology Group. The term matrix, despite having
a long history, had signiﬁcantly changed its meaning in the 80s
and developed hand-to-hand with the transformations of connec-
tive tissue research.
The ﬁrst uses of matrix date from the 1930s to designate the
conglomerate of proteins, sugars and other components which
make up connective tissue (Piez, 1997, pp. 87–88). The term spread
among researchers during the 50s and 60s, and was present in
textbooks on connective tissue and its diseases. One written in
1968 referred to matrix as a ‘‘formless jelly-like’’ substance which
surrounded the cell and helped it anchor onto other cells in order
to form cartilage, tendons or bones (Schubert & Hamerman, 1968,
p. 1). A decade later, adjectives such as formless, inanimate or inert
were abandoned, as the matrix came to involve a rich variety of
molecules, and to be characterised by a ‘‘dynamic interaction’’ with
the cells (Piez, 1997, pp. 90–91). Matrix biology was then deﬁned
as the ﬁeld studying those interactions (Hay, 1982, p. 1).
Researchers involved in matrix biology during the 1980s and
90s unanimously point towards the key role of recombinant DNA
techniques in revealing the complexity of interactions between cell
and matrix, as well as between the diversity of components of con-
nective tissue. Nevertheless, they also stress the importance of the
‘‘multicellular perspective’’ of the ﬁeld in order to analyse the two-
directional connections not only between cell and matrix, but also
from cell to cell through the matrix.21
If then, matrix biology was considerably helped by the recombi-
nant techniques to acquire its new identity, this identity remained
crucially different from that molecular biology was acquiring be-
tween the 1970s and 80s. Whereas at that time, molecular biolo-
gists were mainly concerned with the interactions between the
cell nucleus and the cytoplasm, matrix biologists considered two-
directional connections between cells, using the extracellular
space. The emerging recombinant techniques were being pre-
sented by some molecular biologists as tools unifying biology
(e.g. Hood, 1990), but the sharing of methods could be understood
in different ways. Matrix research was not seen by its practitioners
as a province of molecular biology, but as an independent ﬁeld
with its own evolving problems.
The Manchester Extracellular Matrix Group was an institutional
materialisation of this differential identity. In the mid-late 1980s,
shortly after the renaming of the group, Grant persuaded Boot-
Handford and other former Manchester connective tissue scientists
to apply for funding to return to the University (Wilson, 2008, pp.
85 and ff.). They chose the Wellcome Trust as the most suitable
funding body, though the group’s prior fellowships and grants
had been mainly from the Medical Research Council (MRC) and
the Arthritis and Rheumatism Research Campaign, the new name
of the Empire Rheumatism Council. New private or charitable
foundations, with different health priorities, were rivalling the
19 Both Prockop and Olsen held a medical degree (MD). This, according to Olsen, furnished them with a ‘‘more global view’’ of the biology of the organism and led them to be
more receptive than collagen biochemists towards the recombinant DNA techniques (B. Olsen, interview with author, Harvard Medical School, US, 2008). Molecular biologists had
developed complex interactions with clinical researchers since the foundational period of this discipline in the 1950s. Soraya de Chadarevian has shown this for the investigations
on the three-dimensional structure of haemoglobin and physicians working on sickle-cell anaemia (de Chadarevian, 1998).
20 R. Boot-Handford, interview with author, Wellcome Trust Centre for Cell Matrix Research, University of Manchester, UK, 2008.
21 M. Grant, R. Boot-Handford and M. Humphries, interviews with author, Faculty of Life Sciences and Wellcome Trust Centre for Cell Matrix Research, University of Manchester,
UK, 2008.
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post-World War II charities and the MRC as the main funders of
British biomedicine.22
The other two researchers whom Grant decided to sponsor re-
ﬂected the wide array of instruments, practices and experimental
approaches gathered in matrix biology. Martin Humphries had mi-
grated to the National Cancer Institute of the NIH in the early
1980s following a PhD at Manchester University’s Department of
Biochemistry, which he started before the merger with Medical
Biochemistry and integration with Grant’s group. He had worked
on the protein ﬁbronectin, also part of connective tissue and
involved in cell growth and adhesion. Karl Kadler, like Boot-
Handford, had worked at Prockop’s laboratory, but his focus was
on electron microscopy of collagen. His PhD had been at the
University’s Department of Medical Biophysics, which like Grant
and Jackson’s group had been founded by former researchers of
the Rheumatism Centre. Neither Humphries nor Kadler used
recombinant DNA regularly: for them it was ‘‘a complement’’
rather than the main tool of their research.23
In their applications for Wellcome funding, Humphries and Ka-
dler both mentioned recombinant techniques, but as ancillary to
other tools to be incorporated to the Extracellular Matrix Group.
Humphries sought a ‘‘combination of peptide chemistry, cell biol-
ogy and molecular biology approaches’’ to study a region of ﬁbro-
nectin linking the protein to the cell. In the NIH, he had used cDNA
cloning to obtain the gene for a particular ﬁbronectin, but his main
approaches in the study of the protein were biochemistry and cell
biology.24 Kadler worked with enzymatic cleavage and mutant col-
lagen, occasionally using sequencing. But in his Wellcome applica-
tion he stressed biophysical approaches to the structure of
collagen ﬁbres, using light and electron microscopy to study the
assembly of the protein.25
The Wellcome approved both applications, and Kadler and
Humphries joined Boot-Handford as returnees to Manchester be-
tween 1987 and 89. In the early 1990s, Grant proposed to theWell-
come the establishment of a reference centre for cell matrix
research in Manchester. At that time, the Wellcome was beginning
to sponsor national specialised centres in different ﬁelds, such as
developmental biology in Cambridge and human genetics in
Oxford.26 The Manchester bid was issued in 1993 by Grant, Kadler,
Humphries and John Sheehan, another researcher in thematrix group.
The centre bid stressed the ‘‘strengths’’ of the Manchester group
in the ‘‘chemistry, biophysics, cell biology and molecular biology’’
of the extracellular matrix. The Manchester researchers, according
to the application, possessed expertise in the technologies of ‘‘elec-
tron microscopy, structural molecular biology and image analysis,
protein crystallography, recombinant DNA technology, transgenic
animal techniques, molecular graphics and computation, and high
ﬁeld n.m.r. [nuclear magnetic resonance]’’.27 Structural molecular
biology and recombinant DNA were two among many disciplines
and tools. They may be seen as key exemplars of the profusion of
analytical ways of knowing and working which were now character-
istic of biomedical research and used not only in molecular biology,
but across many other ﬁelds (Pickstone, 2007a, especially pp. 513–
514).
The group proposed a series of shared laboratories at the Matrix
Centre devoted to ‘‘biomolecule assembly and dynamics’’, ‘‘cell cul-
ture’’ and ‘‘biomolecule puriﬁcation and analysis’’. The former facil-
ity was devoted to electron microscopy and biophysics approaches,
while the latter included a DNA synthesiser, and other protein
sequencing and analysis techniques. The cell culture suit was aimed
to produce mRNA and protein molecules to be analysed (see
Fig. 2).28 Here we also see synthetic molecular biology techniques
combined with analytic instruments from biophysics, biochemistry
and cell biology, and all focused on the study of the extracellular ma-
trix. The new automatic DNA synthesisers were being incorporated to
the historical strengths of the Manchester researchers in cell culture
and electron microscopy, and this resulted in the redeﬁnition of con-
nective tissue as both an object and a research ﬁeld.
Pat Goodwin, one of the Wellcome Trust ofﬁcers involved in
processing the application, has claimed that the main reason for
its success was the ‘‘ﬁne combination’’ of recombinant DNA with
instruments and perspectives ‘‘from biophysics’’. The rise of the re-
combinant techniques in the preceding decades had led most con-
temporary applications to use them in reductionist studies, mainly
focused on the analysis of DNA. The Manchester bid, on the con-
trary, presented such techniques as tools to be combined with oth-
ers in an integrated approach to the cell matrix. This argument is
reinforced by Ramirez, Prockop’s former collaborator, who re-
viewed the application and considered it the beginning of a speciﬁc
line of research pursued by Manchester without the necessity of
‘‘following others’’.29
The Wellcome Trust Centre for Cell Matrix Research opened in
1996. Its foundation represents the emergence of a biomedical
ﬁeld derived from connective tissue research but shaped by a
new conﬁguration of tools, institutions, patronage and research
orientation. This particular conﬁguration, and its opportunity with-
in the transformation of British biomedicine, was essential for the
success of the Matrix Centre over other institutions30 and the rise of
the biomedical sciences in Manchester.
4.1. Automation and spread of recombinant techniques
The new Centre for Cell Matrix Research, as the School of Bio-
logical Sciences had done the decade before, emphasised the use
22 During the late 1980s and early 90s, the Wellcome Trust was becoming a wealthier institution due to the gradual sale of the pharmaceutical company Wellcome Foundation.
In 1995, the majority of the shares of Wellcome Foundation were transferred to Glaxo Laboratories for four billion dollars (Wilson, 2008, p. 83). Boot-Handford was the only early
Manchester matrix researcher whose return was not funded by the Wellcome Trust, but by a fellowship from the Royal National Institute of the Blind to investigate diabetes. The
application seems to have disappeared; neither the applicant nor the institutional archives involved in the process hold a copy of this material.
23 M. Humphries and K. Kadler, interviews with author, Wellcome Trust Centre for Cell Matrix Research, University of Manchester, UK, 2008.
24 M. Humphries (1987) ‘‘Characterisation of cell adhesion sites within ﬁbronectin’’ (Martin Humphries’s personal archive, Wellcome Trust Centre for Cell Matrix Research,
University of Manchester, UK, p. 2).
25 K. Kadler (1988) ‘‘Biochemistry of matrix in normal and diseased connective tissue’’ (Karl Kadler’s personal archive, Wellcome Trust Centre for Cell Matrix Research,
University of Manchester, UK, pp. 3 and ff.).
26 P. Goodwin, interview with author, Wellcome Trust, London, UK, 2008.
27 M. Grant, M. Humphries, K. Kadler, and J. Sheehan (1993) ‘‘The establishment of a Wellcome Cell-Matrix Research Unit—Bid for refurbishment costs, equipment and
infrastructure’’ (Michael Grant’s personal archive, Faculty of Life Sciences, University of Manchester, UK, p. 4).
28 M. Grant, M. Humphries, K. Kadler, and J. Sheehan (1993) ‘‘Equipment justiﬁcation’’ (Michael Grant’s personal archive, Faculty of Life Sciences, University of Manchester, UK)
and M. Grant, M. Humphries, K. Kadler, and J. Sheehan (1993) ‘‘The establishment of a Wellcome Cell-Matrix Research Unit—Bid for refurbishment costs, equipment and
infrastructure’’ (Michael Grant’s personal archive, Faculty of Life Sciences, University of Manchester, UK, pp. 6 and ff.).
29 P. Goodwin and F. Ramirez, interviews with author, Wellcome Trust, London, UK, and Mount Sinai Medical Centre, New York, US, 2008.
30 Other British institutions working on connective tissue took different research directions between the 1980s and 90s. The Kennedy Institute for Rheumatology in London
began at that time to experiment with animal models of collagen diseases, whereas the Strangeways Research Laboratory—the ﬁrst home institution of Crick after his arrival to
Cambridge—abandoned connective tissue to focus on genetic epidemiology. The Unit for Collagen Research at the University of Bristol maintained a veterinary orientation and its
links to the meat industry. Tim Hardingham, biochemist at the Kennedy Institute, moved to Manchester when the Matrix Centre opened and shifted his research to tissue
engineering of cartilage using recombinant DNA (T. Hardingham, interview with author, Wellcome Trust Centre for Cell Matrix Research, University of Manchester, UK, 2008).
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of recombinant DNA in its publicity when it opened (Wilson, 2008,
pp. 86–89). However, these techniques remained initially conﬁned
to Boot-Handford and Grant’s team within the Manchester matrix
biologists. Grant and Boot-Handford incorporated human geneti-
cist Gillian Wallis and biochemist Cay Kielty to their group before
the move to the new Centre. During the early 1990s, they used
cloning and sequencing to construct cDNA libraries of the chick
and human gene for collagen type X (Thomas, Kwan et al., 1991;
Thomas, Cresswell, et al., 1991). The sequence and expression pat-
terns of the gene were then analysed by Boot-Handford (Kong
et al., 1993; Thomas et al., 1995).
The expertise in sequencing and cloning gave Boot-Handford
considerable inﬂuence, as ‘‘the only British scientist in the ﬁeld’’
who had mastered the techniques. At that time, sequencing and
cloning were labour-intensive procedures described by their
inventors in protocols and textbooks. They could be taught at the
bench and circulated from one researcher to other. During the ﬁrst
half of the 1990s, Boot-Handford taught sequencing and cloning to
other University staff, especially in the areas of pathology and clin-
ical medicine. Nevertheless, most of the Extracellular Matrix Group
was initially uninterested in his teaching: the older researchers re-
sisted the potentialities of recombinant DNA, while most of the
young staff ‘‘did not need the techniques’’ for their work.31
The team created by Humphries soon became another focus of
techniques from molecular biology. However, the key technical
expertise was derived from London—and again from genetics—
rather than from Humphries’ stay at the NIH. In the mid 1990s,
Humphries hired a former undergraduate colleague, Linda Green,
with the speciﬁc aim of applying the Polymerase Chain Reaction
(PCR) to the ﬁbronectin project.32 Green had learnt this method at
the Middlesex Medical School, in the context of genetic diagnosis
of brain tumours. Her job was isolating mRNA in rats and multiply-
ing it with PCR, in order to form cDNA libraries and detect the mark-
ers of the tumours through Southern Blot—i.e. complementary DNA
probes.
Green’s work at the matrix group, like Boot-Handford’s, relied
on manual protocols compiled during her previous job. The proto-
cols derived from oral instructions, published papers and unpub-
lished notes written by other researchers (see Fig. 3).33 They
were the foundations of Green and Boot-Handford’s teaching of
the techniques to other investigators. Green also devoted a substan-
tial part of her PhD thesis—conducted after her arrival to Manches-
ter—to the optimisation of manual PCR for the study of genes
producing ﬁbronectin (Green, 1994, pp. 73–77 and 86–91).
But as Green and Boot-Handford were teaching their protocols,
automatic instruments became available for recombinant DNA
work. From the mid 1980s onwards, Applied Biosystems, Cetus
Corporation and other biotechnology companies marketed devices
which conducted sequencing and PCR withminimum human inter-
vention (Chow-White & García-Sancho, in press; García-Sancho,
Fig. 2. Plans for the newWellcome Centre for Cell Matrix Research at the University of Manchester (bottom left) and one of the proposed shared laboratories, as conceived in
1993 (bottom right). Top, from left to right, Martin Humphries, Tim Hardingham, Michael Grant, Karl Kadler and John Sheeham, some of the cell matrix researchers (Michael
Grant’s personal archive, Faculty of Life Sciences, University of Manchester, UK, and Wilson, 2008, p. 87. Reproduced with permission).
31 R. Boot-Handford, interview with author, Wellcome Trust Centre for Cell Matrix Research, University of Manchester, UK, 2008.
32 M. Humphries, interview with author, Wellcome Trust Centre for Cell Matrix Research, University of Manchester, UK, 2008.
33 Manual protocols were also crucial for the introduction of recombinant DNA into the teams working on the haemoglobin gene during the mid and late 1970s (see second half
of Section 3). Ramirez, a researcher involved in both haemoglobin and collagen research, initially based his experiments on a Xeroxed copy of the cloning protocols from
molecular biologist Tom Maniatis. He referred to these protocols as ‘‘the Bible’’ (F. Ramirez, interview with author, Mount Sinai Medical Centre, New York, US, 2008). Maniatis
further published a textbook which became a fundamental source in the circulation of cloning and other recombinant DNA techniques (Maniatis, 1982). On the role of protocols in
the circulation of practices and instruments see Lynch, Cole, McNally, & Jordan (2009, pp. 87 and ff.).
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2008, pp. 167–193; Rabinow, 1996). These instruments spread
among the biomedical community and by the early and mid 90s
were permeating many day-to-day laboratory activities (Jordan &
Lynch, 1992; Jordan & Lynch, 1993; Keating, Limoges, & Cambrosio,
1999; Ramillon, 2007).
The Manchester Matrix Centre incorporated some of these auto-
matic devices. The Wellcome Trust application to create the Centre
included a DNA synthesiser and an automatic protein sequencer.34
Shortly after its submission, in 1995, Professor of Dental Genetics,
Michael Dixon, led a new Wellcome grant proposal to acquire an
automatic DNA sequencer for the whole Faculty of Life Sciences. In
line with the philosophy of the University’s reform, the sequencer
and associated equipment would be used as centralised and shared
facilities.35 The applicants, among them Humphries, secured funds
to buy a 377 DNA sequencer, which was marketed by Applied
Biosystems.
The sequencer and other contemporary automatic devices led
to the spread of recombinant DNA across the groups of the Matrix
Centre. In 1999, Dixon issued an application for renewal and main-
tenance funds to theWellcome and, by that time, ﬁve matrix teams
had used or were planning to use the sequencer.36 The availability
and increasing user-friendliness of these automatic devices made
researchers less dependent on Green and Boot-Handford, and able
to perform sequencing and PCR autonomously. These researchers
were, at the same time, increasingly unaware of the biological
mechanisms underlying sequencing and PCR, which they saw simply
as tools. Thus the techniques became both more pervasive and more
‘‘blackboxed’’ (Latour, 1987, ch. 3). By the late 90s, Green and Boot-
Handford were only called on by other matrix researchers when the
devices would not work properly.37
5. Conclusions
The transformation of connective tissue research into cell ma-
trix biology in Manchester between the 1940s and 90s constitutes
a suitable case for integrating the different levels, perspectives and
timeframes of STS literature on biomedicine. It shows how global
shifts in the organisation of the British and US biomedical com-
plexes—triggered by socio-political changes and the emergence
of biotechnology in the late 70s—affected the local biomedical plat-
forms integrated by Michael Grant and Darwin Prockop’s collagen
research groups. The advent of recombinant DNAmethods fostered
institutional reforms—with new undergraduate courses, schools
and university departments—and changed the conﬁguration of
tools and patterns of work of biomedical investigators. It also
transformed the way in which the Manchester researchers inte-
grated the biological and the medical.
Connective tissue research in Manchester emerged as a conse-
quence of the rise of biomedicine after World War II and, more
concretely, the medical concern with rheumatism and arthritis,
Fig. 3. List of protocols used by Boot-Handford during the 1990s in Manchester (above) and one of his cDNA synthesis procedures (below) (Raymond Boot Handford’s
personal archive, Wellcome Trust Centre for Cell Matrix Research, University of Manchester, UK. Reproduced with permission).
34 M. Grant, M. Humphries, K. Kadler, and J. Sheehan (1993b) ‘‘Equipment justiﬁcation’’ (Michael Grant’s personal archive, Faculty of Life Sciences, University of Manchester, UK,
pp. 3–4).
35 M. Dixon, M. Humphries, G. Brady, J. Hewitt, and K. Gull (1995) ‘‘An integrated DNA sequencing facility for studies of genome analysis and gene organisation’’ (Michael Dixon’s
personal archive, Faculty of Life Sciences, University of Manchester, UK, pp. 4–8c).
36 M. Dixon, M. Humphries, and K. Gull (1999) ‘‘Equipment for semi-automated, ﬂuorescence-based DNA sequencing’’ (Michael Dixon’s personal archive, Faculty of Life Sciences,
University of Manchester, UK, pp. 6–10c).
37 R. Boot-Handford, inverview with author, Wellcome Trust Centre for Cell Matrix Research, University of Manchester, UK, 2008.
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including new treatments. Clinicians and MDs such as Prockop,
Jonas Kellgren and Bjorn Olsen played a leading role in its develop-
ment, in cooperation with biochemists, biophysicists, histopathol-
ogists and cell biologists. During the last third of the 20th century,
the ﬁeld gradually evolved towards more fundamental research
and this was eased by the University reform, the rise of preclinical
and biological sciences in Manchester, the emergence of the
Extracellular Matrix Group, and the new focus on diseases such
as cancer or diabetes. In this way, connective tissue research differs
from the history of other post-World War II lines of biomedical
research, which evolved from fundamental to the clinical (e.g. De
Chadarevian, 2002).
The advent of recombinant DNA and its perception as ‘‘the right
tool for the job’’ by funders and governments (Clarke & Fujimura,
1992) was decisive for the transformation of connective tissue re-
search and the emphasis that investigators placed on these new
technologies—partly to attract funding and prestige—may suggest
that they replaced previous tools and concerns. This was not the
case in the Manchester group, however, where cDNA cloning,
sequencing and PCR interacted with long-standing instruments
and problems in the study of connective tissue, such as cell culture,
electron microscopy and collagen biosynthesis. The new tech-
niques, moreover, had needed to be repackaged in human genetics,
a medically-oriented ﬁeld which was closer to the interests and
model organisms of the connective tissue researchers. And they
did not permeate all the lines of research on matrix biology until
blackboxed in automatic devices established as centralised and
shared facilities.
The Manchester case, in sum, suggests a long-term strategy of
‘‘molecularisation’’ (De Chadarevian & Kamminga, 1998) in which
an array of instruments and biological ﬁelds interacted with a
long-standing medical problem: the role of connective tissue in
health and disease. It also illustrates the considerable and some-
times contested ‘‘cumulations’’ of analytical techniques—such as
electron microscopy and sequencing—in recent biomedical re-
search (Pickstone, 2007a, p. 515). Though these techniques could
help create new technical specialisations, the sharing of methods
and the common reference to genes and proteins could be claimed
as a uniﬁcation of biology.
We have seen that in Manchester, the new School of Biological
Sciences which replaced a number of biological and pre-clinical
departments was meant to focus on molecular biology, with only
weak internal divisions. When we look more closely, however, we
see the continuity of a research programme, acquiring new meth-
ods alongside their old methods, and retaining a clinical dimension,
even as the ﬁeld of study deepened. We see apparently simple
structural and functional relations in cartilage re-understood as
complex interactions, so that matrix biology could emerge as one
key ﬁeld of biology, in parallel and in connection with many other
such ﬁelds.When the School of Biological Scienceswas transformed
into a Faculty in 1993, it was to contain research groups instead of
departments. Its structure seemed to reﬂect the shared methods
and facilities, but also the different foci and problems that gave
meaning to most research careers, and which were related in com-
plex ways to patterns of training and to disciplinary organisations
such as professional societies and their journals.
For all the good work on molecular biology, historians have
hardly begun to analyse these dynamic dialogues between diver-
gent and unifying concerns, analytical and synthetic approaches,
research projects and disciplines, or between patterns of work
and academic (and related) structures. I have tried to show some
of the interactions for one University and one research ﬁeld. We
will need many more cases and comparative analyses to under-
stand the typical moves, the contextual differences, and indeed
the continuities across the so-called bioscience revolution of the
late 20th century.
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